Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Vertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.